Patents by Inventor Daniele Andreotti

Daniele Andreotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220396581
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: April 12, 2021
    Publication date: December 15, 2022
    Applicant: Janssen BioPharma, Inc.
    Inventors: Guangyi WANG, Leonid BEIGELMAN, Anh TRUONG, Carmela NAPOLITANO, Daniele ANDREOTTI, Haiying HE
  • Publication number: 20220363640
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: March 22, 2021
    Publication date: November 17, 2022
    Applicant: Janssen BioPharma, Inc.
    Inventors: Guangyi WANG, Leonid BEIGELMAN, Anh TRUONG, Carmela NAPOLITANO, Daniele ANDREOTTI, Haiying HE, Karin Ann STEIN
  • Patent number: 11427558
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Albert W. Garofalo, St├ęphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Publication number: 20220162192
    Abstract: The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Albert W. Garofalo, St├ęphane De Lombaert, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • Publication number: 20210261553
    Abstract: The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 26, 2021
    Inventors: Albert W. Garofalo, Daniele Andreotti, Silvia Bernardi, Elena Serra, Marco Migliore, Fabio Maria Sabbatini, Claudia Beato, Paolo Vincetti, Federica Budassi
  • Patent number: 11021444
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Patent number: 11014935
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • Publication number: 20210130306
    Abstract: The present application provides malonamide compounds, and derivatives thereof (e.g., N-aryl malonamides (NAM), acetamides, oxalamides, and the like), that are useful, for example, for the treatment of acute, chronic/persistent, and/or relapsing infections. Pharmaceutical compositions, methods of treating diseases (e.g., bacterial infections), and methods of reducing bacterial virulence are also provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 6, 2021
    Inventors: Laurence Rahme, Francois Lepine, Damien Maura, Carmela Napolitano, Antonio Felici, Michele Negri, Stefano Fontana, Daniele Andreotti
  • Publication number: 20200190090
    Abstract: The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as medicaments, in particular for treating diseases, disorders, or conditions mediated by orexin receptor activity. More specifically, there is provided a compound of Formula (I) including salts thereof, polymorphs, and isomers thereof (including optical, geometric and tautomeric isomers) as defined herein and isotopically-labelled compounds of Formula (I).
    Type: Application
    Filed: May 10, 2018
    Publication date: June 18, 2020
    Applicant: Benevolentai Bio Limited
    Inventors: David SHEPPARD, Daniele ANDREOTTI
  • Publication number: 20190263754
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: October 19, 2018
    Publication date: August 29, 2019
    Applicant: Alios BioPharma, Inc.
    Inventors: Guangyi WANG, Leonid BEIGELMAN, Anh TRUONG, Carmela NAPOLITANO, Daniele ANDREOTTI, Haiying HE, Karin Ann STEIN
  • Publication number: 20180065932
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: August 16, 2017
    Publication date: March 8, 2018
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Publication number: 20170283429
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • Patent number: 9724351
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: August 8, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • Patent number: 9365551
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: June 14, 2016
    Assignee: Glaxo Group Limited
    Inventors: Daniele Andreotti, Xuedong Dai, Andrew John Eatherton, Karamjit Singh Jandu, Qian Liu, Oliver James Philps
  • Publication number: 20150238498
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: August 21, 2013
    Publication date: August 27, 2015
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • Publication number: 20150065504
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: August 19, 2014
    Publication date: March 5, 2015
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Patent number: 8933132
    Abstract: The invention relates to novel piperazine compounds of formula (I): to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: January 13, 2015
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: David Norton, Daniele Andreotti, Simon E. Ward, Roberto Profeta, Simone Spada, Helen Susanne Price
  • Patent number: 8778939
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 15, 2014
    Assignee: Glaxo Group Limited
    Inventors: Paula Louise Nichols, Andrew John Eatherton, Paul Bamborough, Karamjit Singh Jandu, Oliver James Philps, Daniele Andreotti
  • Publication number: 20140038976
    Abstract: The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.
    Type: Application
    Filed: January 19, 2012
    Publication date: February 6, 2014
    Inventors: David Norton, Daniele Andreotti, Simon E. Ward, Roberto Profeta, Simone Spada, Helen Susanne Price
  • Publication number: 20130225584
    Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Inventors: Daniele Andreotti, Xuedong Dai, Andrew John Eatherton, Karamjit Singh Jandu, Qian Liu, Oliver James Philps